Goutham Narla, MD, PhD, Icahn School of Medicine at Mount Sinai*

Goutham Narla, MD, PhD
Goutham Narla, MD, PhD

The Narla laboratory focuses on the identification and characterization of the genes and pathways involved in cancer metastasis. By testing the functional role of the KLF6 tumor suppressor gene and its oncogenic splice variant KLF6-SV1, Dr. Narla has identified new signaling pathways regulated by this gene family and provided new insight into cancer diagnosis, prognosis and treatment.

Dr. Narla was the first to identify that KLF6 was a tumor suppressor gene in cancer with his mentor Dr. Scott Friedman. He then went on to identify and characterize the oncogenic splice variant KLF6-SV1 in several different malignancies.

*Now affiliated with University of Michigan.



  1. Narla et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor genein mouse liver and human hepatocellular carcinoma.Oncogene, 26, 4428, 2007.
  2. Narla et al, KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer.Science, 294, 2563, 2001.
  3. Tchirkov et al. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem lab Med, 48, 1167, 2010.
  4. Sangodkar et al. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer, 66, 292, 2009.
  5. Narla, G., et al., KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118:2711â??2721 (2008).
  6. DiFeo et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.Cancer Res, 68, 965, 2008.